4.0
Oct 21, 2018
Anonymous employee
Current employee
Recommend
CEO approval
Business Outlook
Pros
After a number of difficult years AstraZeneca is returning to growth and there are good times ahead. Single site in Cambridge bringing AZ and MedImmune scientists under one roof will be beneficial to both. Many opportunities for scientific collaboration in the Cambridge area.
Cons
Delays to Cambridge HQ construction and occupation. Very flat management structure in IMED makes line management positions and progression few and far between (if that's what interests you)